BR9712587A - ‡cido nucléico, molécula de ácido nucléico, sonda, vetor de expressão recombinante, célula, processos para produzir um polipeptìdeo de h. pylori e para detectar a presença de um ácido nucléico de helicobacter pylori em uma amostra, polipeptìdeo de h. pylori isolado, polipeptìdeos de envelope de célula, celular e secretado de h. pylori ou seus fragmentos, proteìna de fusão, formulação de vacina para a profilaxia ou tratamento de uma infecção por h. pylori, e, processos para tratar ou reduzir um risco de infecção por h. pylori em um sujeito e para produzir uma formulação de vacina. - Google Patents

‡cido nucléico, molécula de ácido nucléico, sonda, vetor de expressão recombinante, célula, processos para produzir um polipeptìdeo de h. pylori e para detectar a presença de um ácido nucléico de helicobacter pylori em uma amostra, polipeptìdeo de h. pylori isolado, polipeptìdeos de envelope de célula, celular e secretado de h. pylori ou seus fragmentos, proteìna de fusão, formulação de vacina para a profilaxia ou tratamento de uma infecção por h. pylori, e, processos para tratar ou reduzir um risco de infecção por h. pylori em um sujeito e para produzir uma formulação de vacina.

Info

Publication number
BR9712587A
BR9712587A BR9712587-3A BR9712587A BR9712587A BR 9712587 A BR9712587 A BR 9712587A BR 9712587 A BR9712587 A BR 9712587A BR 9712587 A BR9712587 A BR 9712587A
Authority
BR
Brazil
Prior art keywords
pylori
nucleic acid
processes
cell
vaccine formulation
Prior art date
Application number
BR9712587-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Douglas Smith
Richard A Alm
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of BR9712587A publication Critical patent/BR9712587A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9712587-3A 1996-10-28 1997-10-28 ‡cido nucléico, molécula de ácido nucléico, sonda, vetor de expressão recombinante, célula, processos para produzir um polipeptìdeo de h. pylori e para detectar a presença de um ácido nucléico de helicobacter pylori em uma amostra, polipeptìdeo de h. pylori isolado, polipeptìdeos de envelope de célula, celular e secretado de h. pylori ou seus fragmentos, proteìna de fusão, formulação de vacina para a profilaxia ou tratamento de uma infecção por h. pylori, e, processos para tratar ou reduzir um risco de infecção por h. pylori em um sujeito e para produzir uma formulação de vacina. BR9712587A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73915096A 1996-10-28 1996-10-28
US75973996A 1996-12-06 1996-12-06
US89192897A 1997-07-14 1997-07-14
PCT/US1997/019575 WO1998018323A1 (en) 1996-10-28 1997-10-28 Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof

Publications (1)

Publication Number Publication Date
BR9712587A true BR9712587A (pt) 1999-10-26

Family

ID=27419246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712587-3A BR9712587A (pt) 1996-10-28 1997-10-28 ‡cido nucléico, molécula de ácido nucléico, sonda, vetor de expressão recombinante, célula, processos para produzir um polipeptìdeo de h. pylori e para detectar a presença de um ácido nucléico de helicobacter pylori em uma amostra, polipeptìdeo de h. pylori isolado, polipeptìdeos de envelope de célula, celular e secretado de h. pylori ou seus fragmentos, proteìna de fusão, formulação de vacina para a profilaxia ou tratamento de uma infecção por h. pylori, e, processos para tratar ou reduzir um risco de infecção por h. pylori em um sujeito e para produzir uma formulação de vacina.

Country Status (19)

Country Link
EP (1) EP0973394A4 (ko)
JP (1) JP2001504329A (ko)
KR (1) KR20000052831A (ko)
CN (1) CN1235513A (ko)
AR (1) AR009600A1 (ko)
AU (1) AU734052B2 (ko)
BR (1) BR9712587A (ko)
CA (1) CA2265523A1 (ko)
EE (1) EE9900176A (ko)
ID (1) ID22065A (ko)
IL (1) IL129397A0 (ko)
IS (1) IS5005A (ko)
NO (1) NO991995L (ko)
NZ (1) NZ334568A (ko)
PL (1) PL333169A1 (ko)
SA (1) SA98180918A (ko)
SK (1) SK34699A3 (ko)
TR (1) TR199900940T2 (ko)
WO (1) WO1998018323A1 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
NZ269124A (en) * 1993-07-27 1997-06-24 Csl Ltd Vaccine comprising helicobacter antigens and its use in treating such infections
DE19730425A1 (de) 1997-07-16 1999-01-21 Henkel Teroson Gmbh Heißhärtende wäschefeste Rohbau-Versiegelung
WO2000006743A2 (en) * 1998-07-27 2000-02-10 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
SE9901548D0 (sv) * 1999-04-29 1999-04-29 Astra Ab Helicobacter pylori antigens
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
AUPQ347199A0 (en) * 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
EP3594334A3 (en) 2000-03-08 2020-03-18 Novozymes A/S Variants with altered properties
GB0010370D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
GB0010371D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
EP2695938B1 (en) * 2011-03-17 2016-11-30 National UniversityCorporation Mie University Antibody production method
JP6959937B2 (ja) * 2015-12-14 2021-11-05 テクニシェ ユニバーシタット ミュンヘン ヘリコバクターピロリワクチン
CN115724922B (zh) * 2022-07-19 2023-08-22 四川大学华西医院 一种幽门螺杆菌疫苗重组蛋白抗原TonB及其制备方法与应用
CN115581201A (zh) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 以茎段为外植体诱导的二倍体月季f1-61的植株再生方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9300139L (sv) * 1993-01-19 1994-07-20 Medicarb Ab Framställning av ett nytt läkemedel

Also Published As

Publication number Publication date
EE9900176A (et) 1999-12-15
ID22065A (id) 1999-08-26
IS5005A (is) 1999-03-18
CN1235513A (zh) 1999-11-17
PL333169A1 (en) 1999-11-22
TR199900940T2 (xx) 1999-09-21
IL129397A0 (en) 2000-02-17
EP0973394A1 (en) 2000-01-26
NZ334568A (en) 2000-04-28
SA98180918A (ar) 2005-12-03
SK34699A3 (en) 2000-04-10
AU5093398A (en) 1998-05-22
AU734052B2 (en) 2001-05-31
KR20000052831A (ko) 2000-08-25
EP0973394A4 (en) 2005-03-30
AR009600A1 (es) 2000-04-26
NO991995D0 (no) 1999-04-27
JP2001504329A (ja) 2001-04-03
CA2265523A1 (en) 1998-05-07
WO1998018323A1 (en) 1998-05-07
NO991995L (no) 1999-06-28

Similar Documents

Publication Publication Date Title
BR9712587A (pt) ‡cido nucléico, molécula de ácido nucléico, sonda, vetor de expressão recombinante, célula, processos para produzir um polipeptìdeo de h. pylori e para detectar a presença de um ácido nucléico de helicobacter pylori em uma amostra, polipeptìdeo de h. pylori isolado, polipeptìdeos de envelope de célula, celular e secretado de h. pylori ou seus fragmentos, proteìna de fusão, formulação de vacina para a profilaxia ou tratamento de uma infecção por h. pylori, e, processos para tratar ou reduzir um risco de infecção por h. pylori em um sujeito e para produzir uma formulação de vacina.
BR9809445A (pt) Polipeptìdeo compreendendo uma porção imunogênica de um antìgeno de m. tubercolosis, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processos para indução de imunidade protetora em um paciente, processo de detecção de tuberculose em um paciente,e , kit de diagnóstico.
KITAHARA et al. Large-scale purification of porcine calpain I and calpain II and comparison of proteolytic fragments of their subunits
MY120693A (en) Human bikunin
AU7201287A (en) Recombinant human endothelial cell growth factor
BR9307510A (pt) Molécula de ácido nucleico purificada e isolada plasmídeo recombinante adaptado para transformação de hospedeiro vector recombinante adaptado para transformação de célula hospedeira proteína purificada e isolada proteína de membrana externa d15 peptídio sintético molécula quimérica composição imunogênica e anti-soro ou anticorpo
BR0015137A (pt) Peptìdeos antigênicos de neisseria
Park et al. Different forms of adrenal phenylethanolamine N‐methyltransferase: Species‐specific posttranslational modification
NZ536232A (en) Chimeric camp factors for vaccination against streptococcus infection
Valentini et al. Mammalian single-stranded DNA binding proteins and heterogeneous nuclear RNA proteins have common antigenic determinants
BR9714133A (pt) ácido nucleico isolado, molécula do mesmo, sonda, vetor de expressão recombinante, célula, polipeptìdeo, proteìna de fusão formulação de vacina e processos para produzir um polipeptìdeo de h. pylori, para detctar a presença de um ácido nucleico de helicobacter em uma amostra, para tratar ou reduzir um risco de infecção por h. pylori em um indivìduo e para produzir uma formulação de vacina
ES8704735A1 (es) Un procedimiento para la obtencion de un anticuerpo monoclo-nal
Boime et al. The synthesis of human placental lactogen by ribosomes derived from human placenta
DK0419878T3 (da) Nye aprotinin-varianter og genteknologisk fremgangsmåde til mikrobiel fremstilling af disse varianter i homogent processeret form
NO984491L (no) SCF-analogpreparater og fremgangsmÕte for fremstilling av disse
Senior et al. Comparison of the elastolytic effects of human leukocyte elastase and porcine pancreatic elastase
Isobe et al. Isolation and characterization of des (Ala-Lys) calmodulin in porcine brain
AU5776799A (en) Modified hcv peptide vaccines
Langlais et al. The phospholipase A2 of human spermatozoa; purification and partial sequence
Boulton et al. Abnormal human myoglobin: 53 (D4) glutamic acid→ lysine
Desai et al. Carboxyl-terminal sequence of the glycine-arginine-rich histone from bovine lymphosarcoma, Novikoff hepatoma and fetal calf thymus
Tan Isolation and characterization of two toxins from the venom of the Malayan cobra (Naja naja sputatrix)
Campbell et al. Erythropoietin: III. Chemical charactirization of highly purified fractions from sheep erythropoietin concentrates
Kubo Variability in heat-induced fragmentation of a protein in the presence of dodecyl sulfate: the role of an intramolecular sulfhydryl/disulfide exchange
Gimenez et al. Pepsin fragmentation of botulinum type E neurotoxin: Isolation and characterization of 112, 48, 46, and 16 kD fragments

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A,7A,8A, 9A E 10A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.